Telomir Pharmaceuticals Inc
TELO1.390USD
-0.020-1.42%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
42.41MMarket Cap
LossP/E TTM
More Details of Telomir Pharmaceuticals Inc Company
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule designed to lengthen the DNA’s protective telomere caps, thereby promoting longevity in humans and canine animals by treating age-related conditions. TELOMIR-1 is undergoing studies to provide a therapeutic intervention against contracting a number of degenerative and age-related diseases. Its Telomir-1, is being investigated for its potential to address a range of conditions, including Type 2 diabetes, Wilson’s disease, progeria, Alzheimer’s disease, and cancer. The Company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life. It is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal.
Telomir Pharmaceuticals Inc Info
Ticker SymbolTELO
Company nameTelomir Pharmaceuticals Inc
IPO dateFeb 09, 2024
CEOMr. Erez Aminov
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 09
Address900 West Platt Street, Suite 200
CityTAMPA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33606
Phone18138642562
Websitehttps://telomirpharma.com/
Ticker SymbolTELO
IPO dateFeb 09, 2024
CEOMr. Erez Aminov
Company Executives of Telomir Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Independent Director
Independent Director
487.81K
--
Dr. Matthew P. Del Giudice
Dr. Matthew P. Del Giudice
Director
Director
--
--
Mr. Ned Macpherson
Mr. Ned Macpherson
Director
Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Independent Director
Independent Director
487.81K
--
Dr. Matthew P. Del Giudice
Dr. Matthew P. Del Giudice
Director
Director
--
--
Mr. Ned Macpherson
Mr. Ned Macpherson
Director
Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Nov 1
Updated: Sat, Nov 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bay Shore Trust
20.85%
Mira Pharmaceuticals, Inc
10.91%
McNulty (Brian Patrick)
5.82%
DeJoria (John Paul)
5.50%
The Vanguard Group, Inc.
3.46%
Other
53.46%
Shareholders
Shareholders
Proportion
Bay Shore Trust
20.85%
Mira Pharmaceuticals, Inc
10.91%
McNulty (Brian Patrick)
5.82%
DeJoria (John Paul)
5.50%
The Vanguard Group, Inc.
3.46%
Other
53.46%
Shareholder Types
Shareholders
Proportion
Corporation
31.76%
Individual Investor
16.15%
Investment Advisor
5.31%
Investment Advisor/Hedge Fund
1.50%
Hedge Fund
1.00%
Research Firm
0.76%
Other
43.52%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
97
2.77M
8.57%
-1.11M
2025Q2
89
13.66M
45.90%
+660.23K
2025Q1
87
13.90M
46.70%
+955.11K
2024Q4
74
13.75M
46.22%
+2.38M
2024Q3
65
14.68M
49.58%
+3.19M
2024Q2
47
12.97M
43.79%
+1.79M
2024Q1
17
12.67M
42.78%
+1.58M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bay Shore Trust
6.73M
20.85%
-89.00K
-1.30%
Dec 31, 2024
McNulty (Brian Patrick)
1.88M
5.82%
-49.00K
-2.54%
Dec 31, 2024
DeJoria (John Paul)
1.77M
5.5%
+1.77M
--
Sep 09, 2025
The Vanguard Group, Inc.
1.12M
3.46%
-139.96K
-11.12%
Jun 30, 2025
Aminov (Erez)
1.01M
3.13%
+979.88K
+3288.20%
Dec 31, 2024
Eagle (Craig)
487.81K
1.51%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
357.01K
1.11%
-761.63K
-68.09%
Jun 30, 2025
Millennium Management LLC
247.70K
0.77%
+247.70K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
196.88K
0.61%
-232.37K
-54.13%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
